Gastrointestinal mantle cell lymphoma

Hiroyuki Okada, Tadashi Yoshino, Katsushi Shinagawa, Kazuhide Yamamoto

Research output: Contribution to journalArticle

Abstract

Mantle cell lymphoma (MCL) is a B cell lymphoma derived from the mantle zone of the lymph node follicle. MCL is immunohistochemically positive for CD5 and cyclin D1 and negative for CD10. These markers are useful for a definitive diagnosis. Specific gene abnormalities include a t (11 ; 14) (q13 ; q32) translocation. About 75% of MCL cases are diagnosed at an advanced stage III or IV, with gastrointestinal involvement detected at a high rate. A review of 71 Japanese patients with gastrointestinal involvement of MCL revealed that 67% were diagnosed at stage IV. Gastrointestinal involvement included stomach (2/3) and colon lesions (2/5). Esophageal involvement was uncommon (4 cases). Stomach lesions varied morphologically, including protruded, ulcerative, and fold-thickening types and multiple lymphomatous polyposis (MLP). MCL is often observed as MLP from the duodenum to the colon. The prognosis of MCL is poorer among B cell lymphoma cases, with a median survival of 48-68 months. A hyper-CVAD/MA regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high doses of methotrexate and cytarabine) was designed to improve the therapeutic effects of the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab plus CHOP. Following this therapy, high-dose chemotherapy with autologous peripheral blood stem cell transplantation is performed to improve the rates of complete remission and relapse-free survival.

Original languageEnglish
Pages (from-to)3067-3078
Number of pages12
JournalGastroenterological Endoscopy
Volume55
Issue number9
Publication statusPublished - Sep 2013

Fingerprint

Mantle-Cell Lymphoma
Vincristine
B-Cell Lymphoma
Doxorubicin
Cyclophosphamide
Stomach
Colon
Peripheral Blood Stem Cell Transplantation
Survival
Cyclin D1
Cytarabine
Therapeutic Uses
Prednisone
Duodenum
Methotrexate
Dexamethasone
Lymph Nodes
Recurrence
Drug Therapy
Genes

Keywords

  • Endoscopic figure
  • Gastrointestinal involvement
  • Mantle cell lymphoma

ASJC Scopus subject areas

  • Gastroenterology
  • Radiology Nuclear Medicine and imaging

Cite this

Okada, H., Yoshino, T., Shinagawa, K., & Yamamoto, K. (2013). Gastrointestinal mantle cell lymphoma. Gastroenterological Endoscopy, 55(9), 3067-3078.

Gastrointestinal mantle cell lymphoma. / Okada, Hiroyuki; Yoshino, Tadashi; Shinagawa, Katsushi; Yamamoto, Kazuhide.

In: Gastroenterological Endoscopy, Vol. 55, No. 9, 09.2013, p. 3067-3078.

Research output: Contribution to journalArticle

Okada, H, Yoshino, T, Shinagawa, K & Yamamoto, K 2013, 'Gastrointestinal mantle cell lymphoma', Gastroenterological Endoscopy, vol. 55, no. 9, pp. 3067-3078.
Okada H, Yoshino T, Shinagawa K, Yamamoto K. Gastrointestinal mantle cell lymphoma. Gastroenterological Endoscopy. 2013 Sep;55(9):3067-3078.
Okada, Hiroyuki ; Yoshino, Tadashi ; Shinagawa, Katsushi ; Yamamoto, Kazuhide. / Gastrointestinal mantle cell lymphoma. In: Gastroenterological Endoscopy. 2013 ; Vol. 55, No. 9. pp. 3067-3078.
@article{c37796145604419a8c096959096227b9,
title = "Gastrointestinal mantle cell lymphoma",
abstract = "Mantle cell lymphoma (MCL) is a B cell lymphoma derived from the mantle zone of the lymph node follicle. MCL is immunohistochemically positive for CD5 and cyclin D1 and negative for CD10. These markers are useful for a definitive diagnosis. Specific gene abnormalities include a t (11 ; 14) (q13 ; q32) translocation. About 75{\%} of MCL cases are diagnosed at an advanced stage III or IV, with gastrointestinal involvement detected at a high rate. A review of 71 Japanese patients with gastrointestinal involvement of MCL revealed that 67{\%} were diagnosed at stage IV. Gastrointestinal involvement included stomach (2/3) and colon lesions (2/5). Esophageal involvement was uncommon (4 cases). Stomach lesions varied morphologically, including protruded, ulcerative, and fold-thickening types and multiple lymphomatous polyposis (MLP). MCL is often observed as MLP from the duodenum to the colon. The prognosis of MCL is poorer among B cell lymphoma cases, with a median survival of 48-68 months. A hyper-CVAD/MA regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high doses of methotrexate and cytarabine) was designed to improve the therapeutic effects of the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab plus CHOP. Following this therapy, high-dose chemotherapy with autologous peripheral blood stem cell transplantation is performed to improve the rates of complete remission and relapse-free survival.",
keywords = "Endoscopic figure, Gastrointestinal involvement, Mantle cell lymphoma",
author = "Hiroyuki Okada and Tadashi Yoshino and Katsushi Shinagawa and Kazuhide Yamamoto",
year = "2013",
month = "9",
language = "English",
volume = "55",
pages = "3067--3078",
journal = "Gastroenterological Endoscopy",
issn = "0387-1207",
publisher = "Japan Gastroenterological Endoscopy Society",
number = "9",

}

TY - JOUR

T1 - Gastrointestinal mantle cell lymphoma

AU - Okada, Hiroyuki

AU - Yoshino, Tadashi

AU - Shinagawa, Katsushi

AU - Yamamoto, Kazuhide

PY - 2013/9

Y1 - 2013/9

N2 - Mantle cell lymphoma (MCL) is a B cell lymphoma derived from the mantle zone of the lymph node follicle. MCL is immunohistochemically positive for CD5 and cyclin D1 and negative for CD10. These markers are useful for a definitive diagnosis. Specific gene abnormalities include a t (11 ; 14) (q13 ; q32) translocation. About 75% of MCL cases are diagnosed at an advanced stage III or IV, with gastrointestinal involvement detected at a high rate. A review of 71 Japanese patients with gastrointestinal involvement of MCL revealed that 67% were diagnosed at stage IV. Gastrointestinal involvement included stomach (2/3) and colon lesions (2/5). Esophageal involvement was uncommon (4 cases). Stomach lesions varied morphologically, including protruded, ulcerative, and fold-thickening types and multiple lymphomatous polyposis (MLP). MCL is often observed as MLP from the duodenum to the colon. The prognosis of MCL is poorer among B cell lymphoma cases, with a median survival of 48-68 months. A hyper-CVAD/MA regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high doses of methotrexate and cytarabine) was designed to improve the therapeutic effects of the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab plus CHOP. Following this therapy, high-dose chemotherapy with autologous peripheral blood stem cell transplantation is performed to improve the rates of complete remission and relapse-free survival.

AB - Mantle cell lymphoma (MCL) is a B cell lymphoma derived from the mantle zone of the lymph node follicle. MCL is immunohistochemically positive for CD5 and cyclin D1 and negative for CD10. These markers are useful for a definitive diagnosis. Specific gene abnormalities include a t (11 ; 14) (q13 ; q32) translocation. About 75% of MCL cases are diagnosed at an advanced stage III or IV, with gastrointestinal involvement detected at a high rate. A review of 71 Japanese patients with gastrointestinal involvement of MCL revealed that 67% were diagnosed at stage IV. Gastrointestinal involvement included stomach (2/3) and colon lesions (2/5). Esophageal involvement was uncommon (4 cases). Stomach lesions varied morphologically, including protruded, ulcerative, and fold-thickening types and multiple lymphomatous polyposis (MLP). MCL is often observed as MLP from the duodenum to the colon. The prognosis of MCL is poorer among B cell lymphoma cases, with a median survival of 48-68 months. A hyper-CVAD/MA regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high doses of methotrexate and cytarabine) was designed to improve the therapeutic effects of the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab plus CHOP. Following this therapy, high-dose chemotherapy with autologous peripheral blood stem cell transplantation is performed to improve the rates of complete remission and relapse-free survival.

KW - Endoscopic figure

KW - Gastrointestinal involvement

KW - Mantle cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84886736483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886736483&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84886736483

VL - 55

SP - 3067

EP - 3078

JO - Gastroenterological Endoscopy

JF - Gastroenterological Endoscopy

SN - 0387-1207

IS - 9

ER -